VIR

Over the past six months, Vir Biotechnology's stock price has been influenced by several events. The company reported a larger-than-expected loss in Q1 2026, but the stock rose due to clinical progress and partnerships. The Chairman of the Board sold shares as part of a pre-planned trading plan. The company closed a global strategic collaboration with Astellas for the prostate cancer treatment VIR-5500 and announced the dosing of the first patient in Phase 1 dose-expansion cohorts for VIR-5500. The CEO sold shares. The stock price increased after updated data from an early-stage trial for VIR-5500 demonstrated efficacy. Vir Biotechnology announced a global strategic collaboration with Astellas to advance VIR-5500 for prostate cancer and reported its Q4 and full-year 2025 financial results. Analyst price targets have generally increased due to the Astellas collaboration, positive VIR-5500 data, and progress in hepatitis D programs. The stock has seen a 51.2% increase since the beginning of 2026 and a 101% gain over the past six months as of May 6, 2026.